Dr. Reddy's Laboratories Limited has informed the Exchange about disclosure Under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹1277.00

prior close

₹1280.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.6%+1.4% vs market

Pharmaceuticals peers, median of 149sector-0.9%+1.7% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty 100 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.4

15m

-0.1

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8-0.6+1.4-0.9+1.7

Next day

+1.9+0.0+1.9+0.2+1.6

+1.2+0.1+1.0+0.1+1.1

-0.8-0.2-0.5-0.5-0.2

-4.4-1.1-3.2-2.8-1.6

-4.2-0.4-3.7-1.9-2.2

-6.5-1.1-5.4-4.2-2.3

15d

-2.5+0.7-3.2-3.7+1.2

-1.0-1.4+0.4-6.5+5.5

-3.0-0.5-2.5-7.7+4.7

+1.3+4.2-2.9-6.6+7.9

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's Laboratories has invested Rs. 565,40,77,993 (approximately Rs. 565.4 Crores) in its step-down wholly-owned subsidiary Dr. Reddy's Laboratories LLC, Russia (DRL Russia), acquiring a 45.19% equity stake. This follows the board's earlier approval (November 5, 2024) for a fund infusion of up to Rs. 600 Crores. The money will be used for the working capital needs of DRL Russia, which distributes pharmaceutical medicines in Russia and posted a turnover of Rs. 2,347 Crores in FY2025, up from Rs. 2,084 Crores in FY2024 and Rs. 1,915 Crores in FY2023. The transaction was done through cash consideration and qualifies as a related party transaction since DRL Russia is a subsidiary.

Likely market impact

This is an internal capital infusion into the company's own Russian subsidiary and is unlikely to materially impact the share price. It signals continued operational commitment to the Russian market, which has been a growing revenue contributor for Dr. Reddy's over the past three years.